5th International Symposium on Minimal Residual Cancer
Last Modified: May 11, 2005
Conference Dates: September 11-14, 2005
Conference Location: Fairmont Hotel, San Francisco, CA
Sponsoring Group: International Symposium on Minimal Residual Cancer
Conference Web Page URL: www.ismrc.org
The Detection of Microscopic Disease in Breast Cancer: a Paradigm for Other Solid Tumors
- ICC- and PCR-based strategies
- Microscopic disease in sentinel nodes
- Microscopic disease in bone marrow: when to detect?
- Circulating tumor cells (CTCs): a prognostic or predictive factor?
- MRD in bone marrow: future directions:
- MRD in blood: future directions
- Panel discussion: Cooperation between USA and EU for the development and implementation of methods of detection of MRD in breast cancer
The Detection of Microscopic Disease in Solid Malignancies
- MRD in prostate cancer
- MRD in NSCLC and GI malignancies
- MRD in gynecological cancer
The Biology of MRD: Potential Relevance for Cancer Research Applications
- The biology of metastasis in breast cancer: MRD as a model
- Combined genome/transcriptosome analysis of single disseminated tumor cells
- Genomic profiling and MRD: technology development and future perspectives
- Expression signature of MRD in peripheral blood
- Expression profiling of CTCs in breast and prostate cancer
- Therapeutic targets in MRD
- Glycobiology of solid tumors
- Circulating endothelial cell analysis
- Panel discussion: Single or multiple technologies for determining the biology of MRD
Applications to Clinical Practice
- The development of clinical trials evaluating MRD: Challenges and opportunities. The MRC trialists initiative
Conference Objectives: To report on the most relevant advances in the detection and characterization of minimal residual cancer in solid tumors.
Who Should Attend: Cancer researchers and clinicians
Registration Information: Please refer to www.ismrc.org
Conference Fees: $390- academic, $200 - student prior to July 15
Continuing Education: No
Flow Cytometry Indicates Treatment Response in AML
Sep 13, 2012 - For children with acute myeloid leukemia, minimal residual disease activity, as measured using flow cytometry, is a good indicator of treatment response, with morphologic analysis providing limited additional information, according to a study published online Sept. 10 in the Journal of Clinical Oncology.
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!